ATAD2 is associated with malignant characteristics of pancreatic cancer cells

被引：17
|
作者：
Liu, Nairong [1 ]
Funasaka, Kohei [1 ]
Obayashi, Tomohiko [1 ]
Miyahara, Ryoji [1 ]
Hirooka, Yoshiki [1 ]
Goto, Hidemi [1 ]
Senga, Takeshi [2 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Div Canc Biol, 65 Tsurumaicho, Nagoya, Aichi 4668550, Japan
来源：
ONCOLOGY LETTERS | 2019年 / 17卷 / 03期
关键词：
ATAD2; AAA; pancreatic cancer; gemcitabine; HEPATOCELLULAR-CARCINOMA; COREGULATOR ANCCA; OVEREXPRESSION; FAMILY; BREAST; P97; PROLIFERATION; ANCCA/ATAD2; PROGRESSION; INHIBITORS;
D O I：
10.3892/ol.2019.9960
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pancreatic cancer is one of the most aggressive human cancers and is associated with a poor prognosis. To develop a novel strategy for pancreatic cancer treatment, it is essential to elucidate the molecular mechanisms underlying the invasion and proliferation of cancer cells. ATPase family AAA domain containing protein 2 (ATAD2) is a highly conserved protein with an AAA+ domain and a bromodomain. Accumulating studies have demonstrated that ATAD2 is associated with the progression of multiple cancers. The present study demonstrated that ATAD2 depletion suppressed cell invasion and migration. In addition, ATAD2 knockdown suppressed anchorage-independent growth of pancreatic cancer cells. Finally, ATAD2 depletion was demonstrated to sensitize pancreatic cancer cells to gemcitabine. The results of the present study indicate that ATAD2 is involved in the malignant characteristics of pancreatic cancer.
引用
收藏
页码：3489 / 3494
页数：6
相关论文
共 50 条
  • [41] ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection
    Hwang, Hye Won
    Ha, Sang Yun
    Bang, Heejin
    Park, Cheol-Keun
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 853 - 861
  • [42] Exploring ATAD2 Bromodomain Structure And Function Differences In The Dynamic Epigenetic Landscape
    Malone, Kiera
    Glass, Karen
    Nix, Jay
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2022, 78 : A35 - A35
  • [43] Disulfide bridge formation contributes to histone ligand recognition by the ATAD2 bromodomain
    Evans, Chiara
    Gay, Jamie
    Eckenroth, Brian E.
    Carlson, Samuel
    Lloyd, Jonathan T.
    Glass, Karen C.
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [44] Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors
    Bamborough, Paul
    Chung, Chun-wa
    Furze, Rebecca C.
    Grandi, Paola
    Michon, Anne-Marie
    Sheppard, Robert J.
    Barnett, Heather
    Diallo, Hawa
    Dixon, David P.
    Douault, Clement
    Jones, Emma J.
    Karamshi, Bhumika
    Mitchell, Darren J.
    Prinjha, Rab K.
    Rau, Christina
    Watson, Robert J.
    Wemer, Thilo
    Demont, Emmanuel H.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (15) : 6151 - 6178
  • [45] Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma
    Wang, Xiao-Long
    Wang, Shuo
    Wu, Zhi-Zhong
    Yang, Qi-Chao
    Li, Hao
    Xiong, Hong-Gang
    Wan, Shu-Cheng
    Sun, Zhi-Jun
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (11): : 1598 - 1609
  • [46] Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers
    Caron, C.
    Lestrat, C.
    Marsal, S.
    Escoffier, E.
    Curtet, S.
    Virolle, V.
    Barbry, P.
    Debernardi, A.
    Brambilla, C.
    Brambilla, E.
    Rousseaux, S.
    Khochbin, S.
    [J]. ONCOGENE, 2010, 29 (37) : 5171 - 5181
  • [47] Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers
    C Caron
    C Lestrat
    S Marsal
    E Escoffier
    S Curtet
    V Virolle
    P Barbry
    A Debernardi
    C Brambilla
    E Brambilla
    S Rousseaux
    S Khochbin
    [J]. Oncogene, 2010, 29 : 5171 - 5181
  • [48] Hitting a Moving Target: Simulation and Crystallography Study of ATAD2 Bromodomain Blockers
    Dolbois, Aymeric
    Batiste, Laurent
    Wiedmer, Lars
    Dong, Jing
    Brutsch, Manuela
    Huang, Danzhi
    Deerain, Nicholas M.
    Spiliotopoulos, Dimitrios
    Cheng-Sanchez, Ivan
    Laul, Eleen
    Nevado, Cristina
    Sledz, Pawel
    Caflisch, Amedeo
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (08): : 1573 - 1580
  • [49] Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness
    Hao, Shengyu
    Li, Fan
    Jiang, Pan
    Gao, Jian
    [J]. CELLULAR & MOLECULAR BIOLOGY LETTERS, 2022, 27 (01)
  • [50] Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors
    Demont, Emmanuel H.
    Chung, Chun-wa
    Furze, Rebecca C.
    Grandi, Paola
    Michon, Anne-Marie
    Wellaway, Chris
    Barrett, Nathalie
    Bridges, Angela M.
    Craggs, Peter D.
    Diallo, Hawa
    Dixon, David P.
    Douault, Clement
    Emmons, Amanda J.
    Jones, Emma J.
    Karamshi, Bhumika V.
    Locke, Kelly
    Mitchell, Darren J.
    Mouzon, Bernadette H.
    Prinjha, Rab K.
    Roberts, Andy D.
    Sheppard, Robert J.
    Watson, Robert J.
    Bamborough, Paul
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (14) : 5649 - 5673
12345